Z1
Z1
Z2
Z2
Z3
Z3

About us

Kanova Biopharma was founded by a world-renowned immunologist in Nov. 2015. Based on its cutting-edge research in immunology, Kanova focuses on developing  First-In-Class therapeutic antibodies or innovative combination therapies to treat cancer and autoimmune diseases.

DEVELOPMENT

这是描述信息

NEWS

 

这是描述信息
China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE 2020-12-22
China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE
Jun.19th, 2020 HJB and Kanova Biopharma reached strategic collaboration 2020-08-20
Jun.19th, 2020 HJB and Kanova Biopharma reached strategic collaboration
Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA. 2019-02-19
Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.
Nov.26th, 2018 Kanova had obtained A round of financing with 115 million yuan (RMB) 2020-01-08
Nov.26th, 2018 Kanova had obtained A round of financing with 115 million yuan (RMB)
Previous page
1
这是描述信息

Add

Zhong Guancun Biopharmaceutical Park, NO.5 Kaituo Road,

Haidian District, Beijing City, China, 10084

A1 Northern Building, 218 Xinghu St. Suzhou Industrial Park, Jiangsu Province, China, 215123

COPYRIGHT @2020 Suzhou xinkanghe Biomedical Technology Co., Ltd   苏ICP备19068714号-1   Power by 300.cn Beijing

这是描述信息

Follow us